Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome
- Authors
- Hong, JY[Hong, Jung Yong]; Seo, JY[Seo, Ja-Young]; Kim, SH[Kim, Sun-Hee]; Jung, HA[Jung, Hyun Ae]; Park, S[Park, Silvia]; Kim, K[Kim, Kihyun]; Jung, CW[Jung, Chul Won]; Kim, JS[Kim, Jin Seok]; Park, JS[Park, Joon Seong]; Kim, HJ[Kim, Hee-Jin]; Jang, JH[Jang, Jun Ho]
- Issue Date
- May-2015
- Publisher
- INT INST ANTICANCER RESEARCH
- Keywords
- Myelodysplastic syndrome; SRSF2; U2AF1; ZRSR2; decitabine
- Citation
- ANTICANCER RESEARCH, v.35, no.5, pp.3081 - 3089
- Indexed
- SCIE
SCOPUS
- Journal Title
- ANTICANCER RESEARCH
- Volume
- 35
- Number
- 5
- Start Page
- 3081
- End Page
- 3089
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/44114
- ISSN
- 0250-7005
- Abstract
- Background: Hypomethylating agents, such as azacitidine and decitabine, now constitute one of the mainstays of myelodysplastic syndrome (MDS) treatment. In recent years, novel recurrent mutations in multiple genes encoding RNA spliceosomal machinery (SRSF2, U2AF1, ZRSR2, SF3B1) were revealed. However, the clinical impact of these mutations on the outcomes of treatment of MDS patients with hypomethylating agents has not been described. Patients and Methods: A total of 58 de novo MDS patients were included in the study who had received first-line decitabine treatment. Polymerase chain reaction (PCR) followed by direct sequencing analyses was performed for the spliceosomal machinery genes including SRSF2, U2AF1 and ZRSR2. Results: In the present analysis of 58 Korean MDS patients, mutations in the splicing machinery genes SRSF2,
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.